bm‑t beteiligungsmanagement thüringen gmbh, management company of the PET Private Equity Thüringen GmbH & Co. KG fund and VACT AG acquire a minority stake in Greiz based company AVISO GmbH. The provided capital will be used for launching AVISO’s new “CellCelector”product line.
Dr. Guido Bohnenkamp, General manager of bm‑t, states that “ the sustainable product development, the close cooperation with universities and research institutes as well as the profound professional experience of the company founder and former sole shareholder Reinhard Herrmann were crucial elements of our decision to invest in AVISO”.
According to Frank Hanser, executive chairman of the VACT AG, this decision is “an unique possibility to invest into a beneficial and highly innovative company. This efficiently structured business enables us simultaneously to support the developments for the collective goods, e.g. in regenerative medicine.”
Within a few years, the AVSIO-Team succeeded in developing a worldwide unique technology for cell biological research. The CellCelector and other systems, that are still in the state of development, support the studies in regenerative medicine and in cancer research. One of the first and important customers is the US American White Head Institute who is currently making world news with its achievements in reprogrammable somatic cells to stem cells.
“When regenerative medicine has reached a state in which skin, cartilage or organs can be grown of human somatic cells and transplanted, then we are able to allay pain and to abort diseases. Consequently, we can restore many people’s quality of life. Within this large field of prospects AVISO aims to launch technologies that permit research and industry to faster achieve valuable results”, CEO Reinhard Herrmann says. At present, AVISO maintains research cooperation to many universities and institutes. This close network enables AVISO to directly implement customer demands into the research and development process and ultimately gain a permanent competitive advantage.
AVISO is a competent partner for the development and production of innovative systems for laboratory automation. With the focus on niches with great growth potential within the biotechnology branch AVISO develops its innovations in close cooperation with customers and research institutes in Europe, Asia and Northern America. Resulting from this partnership are products with highly international market acceptance. In 2005, the AVISO has taken over the automation branch of the MWB Biotech AG and thereby increased its portfolio of liquid handling systems. The company operates on the markets in Germany, UK, and France and in the US with an own service and sales structure. Moreover, the AVISO is a long-time experienced partner in OEM business. Together with its customers they develop and produce assemblies and instruments which are in use all over the world.
VACT has developed an equity and mezzanine product “Faszination Mittelstand” that focuses on small and medium sized businesses in Germany. The company has invested in industries such as security and communications, services, medical engineering and energy and environmental technology.
Assistant to Management
T: +49 365 55 191–42
F: +49 365 55 191–43
Frank K. M. Hanser
Erdinger Straße 84
T: +49 8161 23471–0
F: +49 8161 23471–9